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Abstract
Background: Hypophosphatasia (HP) is an inborn error of bone metabolism characterized by a
genetic defect in the gene encoding the tissue-nonspecific alkaline phosphatase (TNSALP). There
is a lack of knowledge as to how the variability and clinical severity of the HP phenotype (especially
pain and walking impairment) are related to metabolic disturbances or impairments, subsequent to
the molecular defect.
Methods: We analyzed the changes in clinical symptoms and the prostaglandin (PG) metabolism
in response to treatment with non-steroidal anti-inflammatory drugs (NSAIDs) in six children
affected by childhood HP. In addition, by exposing HP fibroblasts to pyridoxal phosphate and/or
calcium pyrophosphate in vitro, we analyzed whether the alterations in PG levels are sequelae
related to the metabolic defect.
Results: Childhood HP patients, who often complain about pain in the lower limbs without evident
fractures, have systemic hyperprostaglandinism. Symptomatic anti-inflammatory treatment with
NSAIDs significantly improved pain-associated physical impairment. Calcium pyrophosphate, but
not pyridoxal phosphate, induced cyclooxygenase-2 (COX-2) gene expression and PG production
in HP and normal fibroblasts in vitro.
Conclusion: Clinical features of childhood HP related to pain in the lower legs may be, at least in
part, sequelae related to elevated PG levels, secondary to the primary metabolic defect.
Consequently, NSAID treatment does improve the clinical features of childhood HP.
Background
Hypophosphatasia (HP) (MIM 241510) is an inborn
error of bone metabolism, characterized by a genetic
defect in the gene encoding the tissue-nonspecific alkaline
phosphatase (TNSALP) [1-3]. The HP phenotype displays
considerable clinical variability. Five major subtypes of
HP (perinatal, infantile, childhood, adult and odontohy-
pophosphatasia) have been described [4]. There are bio-
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chemical [5] and molecular data [6-9] indicating that the
severity of the molecular genetic alterations and subse-
quent changes in the levels of TNSALP are major determi-
nants of the clinical phenotype. However, there is a lack of
knowledge about how these features and the severity of
the phenotype are influenced by the molecular defect
and/or subsequent metabolic disturbances or sequelae.
This seems of particular importance since metabolic prod-
ucts accumulating in HP patients, like pyrophosphate
[10,11], have the potential to provoke crystal-induced
arthritis [12-16]. Since milder phenotypes, including the
childhood form of HP, do not reduce the life span of the
affected individuals significantly, there is considerably
more time for such secondary metabolic phenomena to
influence the HP phenotype. We have previously shown
that childhood HP patients commonly complain about
pain in the lower limbs, especially after physical exercise
[17]. In our previous study, symptomatic treatment of HP
patients with one course of non-steroidal anti-inflamma-
tory drugs (NSAID) resulted in a significant clinical
improvement in physical activity and a reduction in pain-
related complaints [17]. So far, no long-term data on such
a symptomatic treatment has been reported. As prostag-
landins (PG) can induce appositional bone growth [18-
20], we hypothesized that elevated PG values might be a
reaction compensating for a mechanically incompetent
bony structure, or it might be a sequel caused by the met-
abolic defect in HP [21]. In order to avoid blocking PG
synthesis for a long period of time, we now have investi-
gated the effect of repeated NSAID treatments, each last-
ing 8 weeks, with an interval of four weeks in between.
We hypothesized that the systemic elevation of PG levels
seen in our patients was due to pyrophosphate stimula-
tion of connective tissue cells including fibroblasts; PG
synthesis by skin and synovial non-hypophosphatasia
fibroblasts has already been established [14]. We, there-
fore, compared the prostaglandin synthesis occurring in
normal as well as in HP fibroblasts exposed to pyridoxal
phosphate and/or calcium pyrophosphate, two of the
metabolic products that accumulate in hypophosphata-
sia. The goal of these analyses was to find out whether
mechanisms secondary to TNSALP deficiency influence
the clinical severity in patients diagnosed with childhood
HP and whether pyrophosphate-stimulated HP fibrob-
lasts are more prone to promote inflammation than
healthy controls.
Patients and methods
Patients
The clinical features, biochemical data, genetic analysis
and clinical effectiveness of a short-term NSAID treatment
have been reported in detail previously, in this cohort of
six patients [21]. In the present study, the same patient
numbering system has been used. Genetic analysis has
been reported previously: Patient #1 belongs to family C,
patient #2 belongs to family E and patient #3 belongs to
family A [9]. No genetic analysis is available for patients
#4, #5 and #6. Six boys with childhood HP aged 2, 2.5, 3,
7.5, 9 and 14 years at initial presentation were followed
up for 4.25, 3.5, 6.5, 4, 4, 3 years respectively, using a pro-
tocol which included patient's history, physical examina-
tion, radiographic imaging (skull, extremities, left
carpus), abdominal ultrasound. Biochemical analysis of
TNSALP metabolism in serum, plasma and urine is shown
in table 1 and includes PG analysis in the urine. Growth,
dental abnormalities, walking ability, kidney function
and craniofacial complications were monitored. Bone
mineral density (BMD) was measured initially and each
year during follow-up. All patients had genua vara or valga
and a waddling gait. Walking was delayed in all patients
by periods ranging from 14 to 24 months (mean: 18
months). Gower's sign was present in five patients. The
walking distance and quality of life was limited by diffuse
pain of the lower legs in all patients. Craniosynostosis was
present in three patients; two patients required a total of
two or three neurosurgical procedures at the cranial vault
for release of the intracranial pressure. Premature loss and
loosening of deciduous teeth, affecting mainly the inci-
sors, was noted in all patients. We have previously
reported the measurement of BMD and markers of bone
metabolism from five kindred including six subjects with
Table 1: Biochemical analyses
patient normal range #1 #2 #3 #4 #5 #6
TNSALP in leukocytes 2–18 nmol/min/mg protein 0.1 0 0.11 0.1 0.1 0.5
PEA in serum/plasma 0–60 µmol/l 25 Nd 98 6 7 97
PEA/Cr in urine 9–25 mmol/mol Cr 252 148 250 157 117 155
PLP in plasma 5–30 ng/ml 1039 408 185 324 446 165
Age years 2 2,5 3 7,42 9 13
Abbreviations:
TNSALP tissue non-specific alkaline phosphatase,
PEA phosphoethanolamin,
Cr creatinine,
PLP pyridoxal phosphateOrphanet Journal of Rare Diseases 2006, 1:24 http://www.OJRD.com/content/1/1/24
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childhood HP [21] who have been further analyzed in this
study.
Bone metabolic profile
The following assays were performed: serum calcium and
phosphate, intact parathyroid hormone (PTH) (1–84
amino acids), TNSALP and total serum alkaline phos-
phatase (AP). In urine, deoxypyridinoline/creatinine
ratio, hydroxyproline/creatinine ratio, calcium/creatinine
ratio and phosphate excretion were measured. Calcium
concentrations were measured by flame atomic absorp-
tion, phosphate and creatinine concentrations were meas-
ured by standard colorimetric assays. Intact PTH was
measured by a 2-site immunoradiometric assay (Nichols
Institute, Bad Nauheim, Germany). Analysis of TNSALP
and its substrates was performed by Y. S. Shin, MD
(Munich, Germany) [22]. Analysis of deoxypyridinoline/
creatinine and hydroxyproline/creatinine levels in the
urine was performed by K. Kruse, MD (†) and O. Hiort,
MD (Lübeck, Germany) using enzyme immunoassays
(Metra Biosystems Inc., Palo Alto, CA, USA) [23].
Systemic prostaglandin E-M (PGE-M) in the urine before and after naproxen treatment in all patients Figure 1
Systemic prostaglandin E-M (PGE-M) in the urine before and after naproxen treatment in all patients. The uri-
nary PG profile was determined prior to, after 8 weeks of treatment and after another 8 weeks of cessation of treatment with 
the NSAID naproxen (15 mg/kg of an oral suspension per day). Treatment cycles were repeated according to clinical necessity, 
especially when the patient's parents reported significant physical impairment due to pain. The levels of PGs and their metabo-
lites were determined in 24-hour urine samples by capillary gas chromatography and mass spectrometry. Systemic prostaglan-
din PGE-M production was evaluated in 15 treatment cycles (connected lines). Eight out of 15 revealed elevated levels above 
the normal range before the start of therapy. All PGE-M levels dropped into the normal range immediately after therapy 
(paired t-test, p = 0.0012). In addition, subsequent PGE-M measurements taken 8 weeks after treatment cessation showed a 
re-elevation in PGE-M levels (paired t-test, p = 0.0011).Orphanet Journal of Rare Diseases 2006, 1:24 http://www.OJRD.com/content/1/1/24
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Prostaglandin profile in the urine during NSAID treatment
The urinary PG profile was determined prior to and after
8 weeks of treatment with the NSAID naproxen (15 mg/kg
per day in oral suspension). Treatment cycles were
repeated according to clinical demands, e.g. when the
patient's parents reported significant physical impair-
ments due to pain. The effectiveness of the first treatment
cycle in each patient has been reported previously [17].
Patients #1–6 received 2, 2, 7 (3 using naproxen, 4 using
meloxicam), 3, 1 and 2 treatment cycles, respectively, each
lasting 8 weeks. Patient #3 had developed pseudoporphy-
ria after the third naproxen treatment cycle [24], therefore
his treatment was switched to meloxicam (0.25 mg/kg
oral suspension per day for 8 weeks). Meloxicam treat-
ment was repeated four times in a prospective manner,
with an 8-week pause in treatment in between, and was
further evaluated for clinical response and laboratory
changes (figures 2,3,4). A final analysis of the systemic
index metabolite of prostaglandin E2 (PGE-M) was per-
formed 8 weeks after the discontinuation of the last mel-
oxicam cycle (treatment 5). Meloxicam oral suspension
was obtained from Boehringer Ingelheim (Biberach, Ger-
many). PGs and their metabolites were determined in 24-
hour urine samples by capillary gas chromatography and
mass spectrometry by H.W. Seyberth, MD (Marburg, Ger-
many) [25], as previously reported [17]. Urinary excretion
rate of PGE2 was used as an index of renal prostanoid
activity. Renal PGE2 production did not change after
treatment (paired t-Test, p = 0.1006). The excretion rate of
7α-hydroxy-5,11-diketotetranorprosta-1,16-dioic acid
Clinical status of patient 3 before and after four meloxicam treatment cycles Figure 2
Clinical status of patient 3 before and after four meloxicam treatment cycles. Patient #3 was followed prospectively 
during four cycles of anti-inflammatory therapy using meloxicam. Each cycle lasted 8 weeks. The clinical status was evaluated 
with a parent's questionnaire and physicians rating using visual analogue scales ranging from 0 to 10 (p calculated by Mann 
Whitney's exact U-test).Orphanet Journal of Rare Diseases 2006, 1:24 http://www.OJRD.com/content/1/1/24
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(systemic index metabolite reflecting systemic levels of
PGE2, PGE-M) was used as an indicator of total body PG
production [25].
This study was funded by University funds only. The treat-
ment was reviewed and approved by the ethics committee
of the University of Würzburg, according to the principles
of the Declaration of Helsinki.
Cell culture
Human fibroblasts were prepared from normal human
skin (control), from skin of a HP patient and from dura
mater of another HP patient (both patients underwent
neurosurgery for release of increased intracranial pressure;
these patients were not included in the biochemical anal-
yses shown below). Tissue samples were prepared by
trypsin enzymatic digestion, maintained in culture fol-
lowing a method described previously [26]. The same
amount of medium out of the same batch was used for the
culture of the cells. Culture conditions between the sam-
ples were kept as comparable and constant as possible.
The study was performed according to the principles of
the Declaration of Helsinki. Isolation and culture of
fibroblasts were approved by the ethics committee of the
University of Würzburg, Germany. Fibroblasts were cul-
tured in 10 cm2 culture plates (Nunc) using RPMI-1640
medium (Invitrogen), supplemented with 10% fetal calf
serum (FCS) (Biochrom KG, Berlin, Germany) at 37°C in
a 5% CO2 humidified incubator. They were used between
passages 10 and 12. For all experiments, fibroblasts (1 ×
105) were seeded in different culture plates and used at a
confluent growth state. Normal and HP fibroblasts were
stimulated with pyridoxal-5-phosphate (C8H10NO6P;
Sigma Aldrich) at 0.5 micrograms/ml of culture medium
for 48 hours in vitro. No pyridoxal-5-phosphate was
present in the RPMI medium, however, pyridoxine hydro-
Laboratory values of patient 3 before and after four meloxicam treatment cycles Figure 3
Laboratory values of patient 3 before and after four meloxicam treatment cycles. For figure legend see figure 2.Orphanet Journal of Rare Diseases 2006, 1:24 http://www.OJRD.com/content/1/1/24
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chloride was present at the same concentration both in
the tested samples and controls. Stimulation with calcium
pyrophosphate (Ca2P2O7; 200 microgram/ml culture
medium, Aldrich) was performed for 48 hours in vitro.
According the manufacturer's analysis, no calcium pyro-
phosphate was present in the RPMI culture medium.
There was no available data on the content of both sub-
stances in the FCS supplement. Pyridoxal-5-phosphate
(PLP) concentration was chosen according to the patients'
blood levels. Calcium pyrophosphate (CPPD) concentra-
tion was chosen according to former publications [14,16].
The experiments were done independently and repeated
four times each. The concentrations of CPPD and PLP in
the supplemented medium were the same in the different
test samples as the same batch of supplemented medium
was used.
Isolation of RNA and synthesis of first strand 
complementary DNA
Total cellular RNA was isolated from fibroblasts of each
individual experimental set using the RNeasy mini kit
(Qiagen) according to Qiagen's protocol. Approximately
the same amount of cells were harvested from each sam-
ple. Contaminating genomic DNA was removed using
RNase-free DNase (Qiagen). Aliquots of RNA from each
experimental set were reversely transcribed into cDNA
using Superscript 2 RNase H reverse transcriptase (RT)
(Invitrogen). The cDNA content of the samples was
Prostaglandin E-M (PGE-M) in the urine of patient #3 during meloxicam treatment Figure 4
Prostaglandin E-M (PGE-M) in the urine of patient #3 during meloxicam treatment. The urinary PG profile was 
determined prior to and after 8 weeks of treatment with the NSAID meloxicam at 0.25 mg/kg oral suspension per day. Treat-
ment cycles were repeated four times prospectively according to a predefined protocol. Therapy cycles were separated by an 
8-week treatment pause. The levels of PGs and their metabolites were determined in 24-hour urine samples by capillary gas 
chromatography and mass spectrometry (p calculated by Mann Whitney's exact U-test). A final PGE-M analysis was done 8 
weeks after discontinuation of the last meloxicam cycle (treatment 5, unconnected X). The   indicates the mean plus 
standard deviation of the different sample sets.Orphanet Journal of Rare Diseases 2006, 1:24 http://www.OJRD.com/content/1/1/24
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adjusted by spectrophotometry. Two negative samples
were prepared, one by adding only RT mix (RT+) without
RNA and another lacking RT (RT-). Positive controls were
run using total RNA isolated from tonsil tissue. The fol-
lowing reagents were added in each tube for the reverse
transcription reaction mix: 8 µl 5X buffer (Invitrogen), 4
µl dTT (0.1 M) (Invitrogen), 2 µl dNTP (Sigma), 2 µl
Superscript 2 RNase H-reverse transcriptase (Invitrogen)
and 1 µl Rnasin (Promega). The reaction mix along with
RNA was initially incubated for 15 minutes at 70°C, fol-
lowed by incubation at 42°C for 50 minutes and 70°C for
15 minutes, finally the tubes were kept on ice for 10 min-
utes. Tubes containing cDNA were stored at -70°C.
Polymerase chain reaction (PCR) was performed to
amplify cDNA of expressed genes of interest. The experi-
ments were repeated four times each.
Quantification of cDNA in samples
For quantification of cDNA in the different samples, PCR
amplification for the housekeeping gene β-actin was per-
formed in triplicate at 25, 30 and 32 cycles each, after the
initial adjustment of the cDNA content was done by spec-
trophotometry. RT-PCR products were analyzed on 1.8%
agarose gels. The gel image was acquired by using a gel
documentation unit (Bio-Rad). The intensities of the PCR
product bands were analyzed by "quantity one" software
(Bio-Rad). The mean counts of the intensities of these tri-
plets in the linear range of PCR amplification were calcu-
lated and were used to calculate the amount of cDNA (in
µl) of each experimental sample that contained the same
relative content of housekeeping gene cDNA, as previ-
ously described [21,27,28]. The calculated volume of
cDNA was subjected to further PCR amplification of
expressed genes of interest. The amplified PCR product
was again analyzed by agarose gel electrophoresis.
Polymerase chain reaction (PCR)
The PCR was performed in a mastercycler (Eppendorf).
The β-actin-adjusted amount of cDNA from the respective
experimental sets was mixed with 20 µl molecular biology
grade water (Eppendorf), 2.5 µl thermophilic DNA poly
10X buffer (Promega), 1.5µl 25 mM MgCl2 (Promega),
0.5µl 10 mM dNTP (Sigma) and 0.25 µl of 50 pmol 3' and
5' primers (MWG, Ebersberg, Germany) in a total volume
of 25 µl. The primer pairs used in the experiment were as
follows:
COX-1 sense 5' GGGCTGATGGTCTTAAATGC 3',
COX-1 antisense 5' GCCAGGAACACAACACTTTG 3',
COX-2 sense 5' CAGCACTTCACGCATCAGTT 3',
COX-2 antisense 5' CAGCAAACCGTAGATGCTCA3',
beta actin sense 5'GTCCTCTCCCAAGTCCACACA3',
beta actin antisense
5'CTGGTCTCAAGTCAGTGTACAGGTAA3'.
All cyclooxygenase (COXs) primer pairs were designed
from the published human cDNA sequence data (NCBI
Genbank) using primer design software (Primer 3', White-
head Institute of Biomedical Research, USA). The PCR of
the target genes was done at the following settings: 5 min-
utes initial denaturation at 95°C in the first cycle, fol-
lowed by 1 minute denaturation at 94°C, 1 minute
annealing at 60°C and 1 minute elongation at 72°C for
all the primer sets. We used 38 cycles for each experiment
to see the expression of our target sequences, as described
previously [27,28]. Experiments were repeated four times
each. Intensities of the PCR product bands were calculated
in a way that allowed comparison of different experi-
ments. PCR band intensities of individual experiments
(pyrophosphate and/or pyridoxal phosphate exposed and
controls) were added and normalized to 100%. The per-
centages of the relative gene expression at a given time
point in the four sets of experiments were added up, and
the mean of relative cDNAexpression was calculated, as
previously described [27,28].
Enzyme linked immunosorbant assay (ELISA)
PGE2 concentrations in the supernatants of exposed and
control fibroblast cultures were assessed using a high sen-
sitivity PGE2 enzyme immunoassay kit (Assay Designs,
Ann Arbor, MI, USA). The kit uses a monoclonal antibody
coupled to alkaline phosphate, which binds PGE2 in a
given sample. ELISA plates were incubated at 4°C for 24
hours after addition of samples, antibody and other
required chemicals in each well. Excess reagents were
washed away and substrate was added, followed by incu-
bation at 37°C for 1 hour. The yellow color generated in
the wells after addition of a stopping solution was ana-
lyzed using a microtiter plate reader at 405 nm. The inten-
sity of the bound yellow color was inversely proportional
to the concentration of PGE2 in the standards and sam-
ples. The measured optical density was used to calculate
the concentration of PGE2, which is shown as the mean of
quadruple experiments in figure 6.
Statistical analysis
Mann Whitney's exact U-test was used for analyzing the
changes in laboratory values (including PG data) and clin-
ical status of patient #3 before and after treatment with
meloxicam. Student's t-test was performed for compari-
son of the PG levels before and after treatment of all
patients [17]. Three-factorial analysis of variance (3-way
ANOVA) was performed to describe differences in the
COX-1, COX-2 gene expression, in addition to PG produc-
tion of fibroblasts in vitro. P values smaller than 0.05 wereOrphanet Journal of Rare Diseases 2006, 1:24 http://www.OJRD.com/content/1/1/24
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considered significant, indicating a difference between the
initial values and the follow-up data. Statistical analysis
was performed by Dr. I. Haubitz.
Results
Bone metabolism in patients
The diagnosis of childhood HP was based on clinical signs
and confirmed in all patients by reduced serum alkaline
phosphatase (AP) activity and elevated AP substrate,
including phosphoethanolamine (PEA), levels in urine
and elevated pyridoxal-5'-phosphate (PLP) in plasma
[21]. TNSALP, measured in leukocytes, was at the lowest
detectable level in all patients (mean 0.15 nmol/min/mg
protein, range 0–0.5 nmol/min/mg protein, normal range
2–18 nmol/min/mg protein) (Table 1). Genetic analysis
of the TNSALP  gene has been previously reported [9].
Serum calcium concentrations were normal and phos-
phate levels were in the upper normal range. Interestingly,
markers of bone turnover, including collagen crosslinks
and hydroxyproline/creatinine levels in the urine, were
unremarkable in all patients. The results obtained for
patient #3 during the long-term prospective NSAID treat-
ment with meloxicam are summarized in figures 2,3,4.
Evaluation of "on demand" NSAID treatment in all 
patients
Previously, we have shown that one single 5-week long
NSAID treatment cycle reduced PG levels in the patients
studied [17]. During the follow-up, the anti-inflammatory
treatment with naproxen was reinitiated in response to
demand from the parents and patients because of clinical
deterioration. Over periods of 4.25, 3.5, 6.5, 4, 4 and 3
years, 2, 2, 7, 3, 1 and 2 treatments, respectively, were
demanded by the patients. Prior to NSAID treatment, the
urinary PGE2 levels, reflecting renal PG production, were
essentially within the normal range. No change was noted
after 8 weeks of NSAID treatment (data not shown, paired
16 t-test, p = 0.1006). When systemic prostaglandin PGE-
M production was evaluated (in 9 out of 15 treatment
cycles) elevated levels (above the normal range) were
COX-2 gene expression in normal and HP fibroblasts exposed to pyridoxal phosphate (PLP) and/or calcium pyrophosphate  (CPPD) Figure 5
COX-2 gene expression in normal and HP fibroblasts exposed to pyridoxal phosphate (PLP) and/or calcium 
pyrophosphate (CPPD). Semiquantitative PCR was performed to analyze the expression of the COX 2 gene in normal and 
HP fibroblasts isolated from the skin and dura mater after exposure to PLP and/or CPPD in vitro. In order to allow compari-
sons, the expression was normalized to a 100% in each of the three groups of fibroblasts. Statistical analysis was done by 3-way 
ANOVA.Orphanet Journal of Rare Diseases 2006, 1:24 http://www.OJRD.com/content/1/1/24
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detected before the therapy was started (figure 1). All PGE-
M levels dropped into the normal range immediately after
therapy (paired t-test, p = 0.0012) and did rise again after
discontinuation of treatment (paired t-test, p = 0.0011)
(Figure 1).
Long-term prospective evaluation of NSAID treatment
Based on our previous study of NSAID treatment [17], we
wanted to prospectively evaluate NSAID treatment in
order to analyze its effects on the clinical status, bone
metabolism and bone mineral density. As indicated in
material and methods, patient #3 was followed during
four cycles of meloxicam treatment over one year. Melox-
icam was selected after the patient developed pseudopor-
phyria after three naproxen treatments. Each treatment
cycle lasted 8 weeks and was followed by a pause of 8
weeks.
The clinical status of this patient (#3) was evaluated using
a questionnaire, which has been evaluated and used pre-
viously [17]. The parents of the patient were asked to esti-
mate overall well-being, physical activity, fatigue, ability
to stand up, aversion to walking, pain in rest and pain
after physical activity, before and after 8 weeks of treat-
ment for each treatment cycle (figure 2) (table 2). In all
these categories a statistically significant improvement
was noted during each treatment cycle (p indicated in fig-
ure 2, Mann Whitney's exact U-Test). After each treatment
pause of 8 weeks, however, the patient's physical status
had worsened again. Each treatment cycle seemed to be of
comparable effectiveness. The overall well-being was eval-
uated by a visual analogue scale from 0 – 10, with 0 indi-
cating extremely reduced and 10 indicating normal.
Physical activity was evaluated on a scale from 0 – 10, 0
indicating less active than normal kids, 5 indicating equal
activity and 10 indicating a higher activity. Fatigue after
physical activity was evaluated on a scale from 0 (rapid
fatigue) to 5 (normal fatigue) to 10 (less fatigue) com-
pared to normal kids after physical activity. The ability to
stand up without the help of the arms was evaluated using
0 (not possible), 5 (significantly reduced) and 10 (not
impaired). The wish to be carried was evaluated with 0
indicating a lot of instances to 10 indicating never.
Whether pain was present during rest was evaluated from
0 (every night and day, very often) to 10 (once in a while,
normal frequency). Pain after physical activity was evalu-
Prostaglandin E2 (PGE2) production by normal and HP fibroblasts exposed to pyridoxal phosphate (PLP) and/or calcium pyro- phosphate (CPPD) in vitro Figure 6
Prostaglandin E2 (PGE2) production by normal and HP fibroblasts exposed to pyridoxal phosphate (PLP) and/
or calcium pyrophosphate (CPPD) in vitro. PGE2 concentrations in the culture supernatant of exposed and control fibro-
blast cultures were assayed using a high sensitivity PGE2 enzyme.Orphanet Journal of Rare Diseases 2006, 1:24 http://www.OJRD.com/content/1/1/24
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ated from 0 (always) to 10 (never). In addition to the par-
ents rating, the overall well-being was also judged by a
"blinded" physician, using the same visual analogue scale
as the parents. The presence of a Gower's sign was rated
from 0 (not present) to 10 (bad, severe muscle weakness
of the lower extremities). In similarity to the parent's rat-
ing, the physician's rating of these two manifestations also
showed a significant improvement of the physical status
of patient #3 during each treatment cycle (Mann Whit-
ney's exact U-Test: p = 0.0079, p = 0.032; respectively)
(figure 2).
Laboratory analysis was done before and immediately
after treatment, including a variety of parameters of bone
metabolism (figure 3). There was no significant change in
the concentration of calcium, phosphate, parathyroid
hormone and creatinine in the serum, measured before
and after treatment. Urinary excretion of hydroxyproline
and deoxypyridinoline did not differ significantly before
and after treatments. Functional analysis of the kidney
including creatinine clearance, phosphate reabsorption
(TRP) and phosphate transport maximum (TmPO4) were
unchanged. All these values were within the normal
range. However, serum alkaline phosphatase, measured
before and after treatment, showed a significant increase
from a mean of 39 U/l to 48.5 U/l (p = 0.032, Mann Whit-
ney's exact U-Test) (figure 3). A selective analysis of TNS-
ALP over time was not performed.
We also evaluated PG concentrations in the urine of
patient #3 as indicated in figure 4. A significant reduction
of systemic PGE-M levels, which were elevated in four out
of five pre-treatment periods, was noted (figure 4) (Mann
Whitney's exact U-Test: p = 0.016). After treatment, the
PGE-M concentration was in the normal range. Renal
PGE2production, which was not elevated before treat-
ment, did not change significantly during the treatment
cycles (Mann Whitney's exact U-Test: p = 0.3).
In vitro cyclooxygenase gene expression in normal and HP 
fibroblasts exposed to pyridoxal phosphate (PLP) and 
calcium pyrophosphate (CPPD)
In order to evaluate a potential stimulation of normal and
HP fibroblasts with PLP and/or CPPD in vitro, COX-1 and
COX-2 gene expression was analyzed in these cells. PGE2
production was assessed by measuring PGE2 concentra-
tion in the supernatant, using the ELISA technique. COX-
1 gene expression did not show a consistent change when
CPPD was added either to normal or to HP skin fibrob-
lasts, or HP fibroblasts isolated from the dura mater (3-
way ANOVA, p = 0.16). In addition, no significant change
was noted when PLP was added to the cultures, compared
to the non-treated cells in each group (3-way ANOVA, p =
0.93). When PLP together with CPPD were added, a slight
statistically insignificant increase in gene expression was
noted in normal and HP skin fibroblasts. However, a
reduction in the gene expression was found in HP dura
mater fibroblasts. None of these changes in COX-1 expres-
sion, however, were statistically significant.
In normal fibroblasts, the addition of PLP did not alter
COX-2 gene expression, whereas in the two HP fibroblast
types, a slight increase of COX-2 production was noted (3-
way ANOVA, p = 0.71) (figure 5). When CPPD was added
to previously non-treated normal or HP fibroblasts, a sig-
nificant increase of COX-2 gene expression was noted in
each fibroblast type (3-way ANOVA, p = 0.0067). When
PLP together with CPPD was added, an increase in COX-2
expression was noted in normal and HP skin fibroblasts,
which was comparable to the stimulation with CPPD
alone (figure 5). When these latter two sets were com-
pared, no significant difference was noted (3-way
ANOVA, p = 0.62), indicating that PLP did not contribute
significantly to the COX-2 gene induction and PG produc-
tion.
Table 2: Clinical evaluation of patient #3 using meloxicam as anti-inflammatory treatment
1. Cycle 2. Cycle 3. Cycle 4. Cycle after 8 wks
time before after before after before after before after pause
overall well being, physician's global rating 69695978 4
G o w e r ' s  s i g n 43545365 6
overall well being, parents' global rating 5 1 0 585978 5
physical activity 2,2 9,6 3,5 7 1,2 7,5 1,2 2,9 2
fatigue after physical activity 0,5 9,3 1,5 5 2,6 5,4 1,5 5,3 1,5
Gower's sign 2,3 6,4 5 6,4 0,8 2,5 1,2 2,9 1,3
patient wants to be carried 1,2 9,3 3,5 5,5 2,9 7,6 2,5 7,6 2,8
pain in rest 3 7 1,8 7 3,25 9,6 1,6 9,5 1,7
pain after physical activity 1,7 7 3,3 5 1,6 7,3 1,9 6,1 1,5Orphanet Journal of Rare Diseases 2006, 1:24 http://www.OJRD.com/content/1/1/24
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When PG concentrations were measured in the culture
supernatant, a significant increase of PGE2 production
was noted after calcium pyrophosphate was added to the
cultures of either normal fibroblasts, HP skin or HP dura
mater fibroblasts (3-way ANOVA, p = 0.011). No effect
was observed when PLP was added to the cultures alone
(3-way ANOVA, p = 0.88). No synergistic effect was noted
when CPPD was added together with PLP (3-way ANOVA,
p = 0.9) (figure 6).
Discussion
Each of the childhood HP patients experienced a signifi-
cant improvement of their physical status when treated
with NSAIDs. This clinical effect was striking and could be
noted in a "treatment on demand" setting involving all
patients, as well as in repetitive treatments involving one
patient. The latter was treated prospectively with the anti-
inflammatory medication meloxicam for one year,
including treatment pauses. Treated patients reported that
the positive effect of the therapy was already noticeable
within a few days after starting the NSAID treatment. After
drug withdrawal, the positive effect on physical activity
persisted for 3–6 weeks. Patient #3 did not experience an
effect lasting longer than 3–4 weeks after NSAID therapy.
This was consistent with a rise in PG levels before each
treatment cycle. An excessive rebound of PG synthesis
after cessation of COX blockade was not noted. An exten-
sive concomitant laboratory analysis did not reveal
changes in bone metabolism, kidney function and parath-
yroid function related to NSAID treatment. However, a
significant increase of alkaline phosphatase activity in the
serum was noted. So far, it is not clear whether this means
an actual increase in TNSALP function or concentration,
or whether it is caused by a variation in sample results
measured at different time points. Nevertheless, it is
important to analyze this particular effect in more detail
in the future, because induction of TNSALP gene expres-
sion might be a therapeutic target in HP.
The pattern in mineralization obtained over the whole
period of four years through bone mineral density meas-
urements in the patient 3 undergoing repetitive treat-
ments did not differ from that obtained from patients
treated on an "on demand" basis for a limited time only.
The improvements in the physical activity noted by the
parents of this child during the treatment cycles, however,
did not seem to influence the dynamics of bone mineral
density to a noticeable extent during the follow-up of 4
years. Initially, we had feared that a PG synthesis blockade
could even worsen bone mineralization, since PGs may
have an inhibitory effect on bone formation rather than a
positive effect. One can only speculate whether a long-
term continuous anti-inflammatory and analgesic therapy
can lead to an improvement or, at least, to a stabilization
of the bony structure, secondary to an improvement of the
physical activity.
In vitro analysis showed that normal and HP fibroblasts
are equally sensitive to calcium pyrophosphate exposure.
A significant increase of COX-2 gene expression and sub-
sequent increase of PGE2 concentrations in the superna-
tant were noted in fibroblasts isolated from normal skin,
HP skin and HP dura mater, after addition of calcium
pyrophosphate but not pyridoxal phosphate. There was
no HP-specific effect, showing that HP fibroblasts are par-
ticularly oversensitive to the exposure of calcium pyro-
phosphate. Thus, this study provides evidence that the
elevation of PGs in HP might be based on the impaired
clearance of calcium pyrophosphate resulting from alka-
line phosphatase deficiency. Our data suggest that PGs
can reduce the physical activity of childhood HP patients
[17]. Physical inactivity could lead to a further impair-
ment of bone mineralization, especially in the back-
ground of this genetic defect. Strenuous physical work
carried out by patient #6 might have contributed to an
increase of bone formation, which reached physiological
levels. In contrast, patient #3, who was treated with
NSAID for a total duration of 32 weeks, showed no
improvement in bone mineral density. Thus, physical
activity seems to have a more positive impact on mineral-
ization in HP than normalization of potentially elevated
PGs alone. Further studies are needed to understand the
secondary metabolic phenomena associated with this
inborn defect of bone metabolism and affecting the sever-
ity of the clinical phenotype.
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